Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
department or school: Other UBC
department or school: Non UBC
data provider: DSpace
identifier citation: BMC Psychiatry. 2016 Apr 16;16(1):105
rights copyright: Lam et al.
creator: Lam, Raymond W
creator: Milev, Roumen
creator: Rotzinger, Susan
creator: Andreazza, Ana C
creator: Blier, Pierre
creator: Brenner, Colleen
creator: Daskalakis, Zafiris J
creator: Dharsee, Moyez
creator: Downar, Jonathan
creator: Evans, Kenneth R
creator: Farzan, Faranak
creator: Foster, Jane A
creator: Frey, Benicio N
creator: Geraci, Joseph
creator: Giacobbe, Peter
creator: Feilotter, Harriet E
creator: Hall, Geoffrey B
creator: Harkness, Kate L
creator: Hassel, Stefanie
creator: Ismail, Zahinoor
creator: Leri, Francesco
creator: Liotti, Mario
creator: MacQueen, Glenda M
creator: McAndrews, Mary P
creator: Minuzzi, Luciano
creator: Müller, Daniel J
creator: Parikh, Sagar V
creator: Placenza, Franca M
creator: Quilty, Lena C
creator: Ravindran, Arun V
creator: Salomons, Tim V
creator: Soares, Claudio N
creator: Strother, Stephen C
creator: Turecki, Gustavo
creator: Vaccarino, Anthony L
creator: Vila-Rodriguez, Fidel
creator: Kennedy, Sidney H
issued: 2016-08-16T16:07:46Z
issued: 2016-04-16
description: Background: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers (“biomarkers”) of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. Methods CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10–20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2–10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. Discussion From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD…
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/58810
note: STUDY PROTOCOL Open AccessDiscovering biomarkers for antidepressantresponse: protocol from the Canadianbiomarker integration network indepression (CAN-BIND) and clinicalcharacteristics of the first patient cohortRaymond W. Lam1, Roumen Milev2, Susan Rotzinger3,4, Ana C. Andreazza4,5, Pierre Blier6, Colleen Brenner7,Zafiris J. Daskalakis4,5, Moyez Dharsee8, Jonathan Downar3,4, Kenneth R. Evans8,9, Faranak Farzan4,5,Jane A. Foster3,10, Benicio N. Frey10, Joseph Geraci3, Peter Giacobbe3,4, Harriet E. Feilotter8,9, Geoffrey B. Hall10,Kate L. Harkness11, Stefanie Hassel12, Zahinoor Ismail13, Francesco Leri14, Mario Liotti15, Glenda M. MacQueen13,Mary Pat McAndrews3, Luciano Minuzzi10, Daniel J. Müller4,5, Sagar V. Parikh16, Franca M. Placenza3,Lena C. Quilty4,5, Arun V. Ravindran4,5, Tim V. Salomons17, Claudio N. Soares18, Stephen C. Strother19,Gustavo Turecki20,21, Anthony L. Vaccarino8, Fidel Vila-Rodriguez1, Sidney H. Kennedy3,4,18* and on behalf of theCAN-BIND Investigator TeamAbstractBackground: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditionsworldwide. Identification of clinical and biological markers (“biomarkers”) of treatment response could personalizeclinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discoverystudy of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker IntegrationNetwork in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers thathelp to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective ofthis initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological,molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy inMDD.(Continued on next page)* Correspondence: sidney.kennedy@uhn.caRaymond W. Lam, Roumen Milev and Susan Rotzinger a…
has type: Article
is shown at: 10.14288/1.0308586
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: BioMed Central
publisher DOI: 10.1186/s12888-016-0785-x
rights: Attribution 4.0 International (CC BY 4.0)
rights URI: http://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
type: Text
identifier URI: http://hdl.handle.net/2429/58810